Delivery Order SPE2DB20D9127-SPE2DB25FPQQ2

Award Date 5/21/25
Potential Completion Date 6/12/25
Potential Value $1.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Park Ridge, IL 60068, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $51,366.90 contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with an ultimate completion date of October 21, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the DLA to issue firm...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.23 contract is for the supply of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a period of performance through June 13, 2025. DMS Pharmaceutical Group has a $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which enables the agency to...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $3,424.46 and a period of performance through May 9, 2025. DMS Pharmaceutical Group holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $1,712.22 contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialized pharmaceutical product, with a period of performance through January 9, 2025. DMS Pharmaceutical Group holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $5,136.69 and a completion date of May 8, 2025. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, which allows the agency to issue firm...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is valued at $3,424.44 and has a period of performance through July 23, 2024. The contract is for the delivery of XOLAIR 150 MG/ML AUTOINJECTORML, a specialty pharmaceutical product. DMS Pharmaceutical Group Inc. holds a larger $499,999,999 indefinite delivery...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract, valued at $6,848.92, is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product. The contract has an ultimate completion date of May 22, 2025. DMS Pharmaceutical Group Inc. holds a larger indefinite delivery contract (IDC) with the DLA under the SPE2DB program, valued at...
This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The $12,841.65 contract is for the supply of XOLAIR 150 MG/ML AUTOINJECTOR medication, with a period of performance through September 18, 2024. DMS Pharmaceutical Group holds a $499,999,999 indefinite delivery contract (IDC) with the DLA under the SPE2DB program, which allows the agency to...
This is a delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, a pharmaceutical product, with a ceiling value of $14,553.95 and a period of performance through May 27, 2025. This award is part of a larger Indefinite Delivery Contract (IDC) valued at $499,999,999 that DMS Pharmaceutical Group...
This is a firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business based in Park Ridge, Illinois. The contract has a ceiling value of $5,136.69 and covers the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML pharmaceutical products. The contract has a period of performance through May 1, 2025. DMS Pharmaceutical Group Inc. holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB...
  • SPE2DB20D9127
    Indefinite Delivery Contract
  • SPE2DB20D9127-SPE2DB25FPQQ2
    Delivery Order

This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois. The contract is for the delivery of XOLAIR 300 MG/2 ML AUTOINJECT 2ML, with a ceiling value of $1,712.23 and a period of performance through June 12, 2025. DMS Pharmaceutical Group holds a larger Indefinite Delivery Contract (IDC) with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which enables the agency to issue delivery orders for a comprehensive range of pharmaceutical items supporting the medical supply needs of military health facilities worldwide. This award is not designated as a set-aside contract.

Generated 8/20/25, 9:58 AM